Stocks
Aktis Oncology, Inc.AKTS
NASDAQHealthcareBiotechnology$16.63
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing targeted radiopharmaceuticals for the treatment of cancer, with a lead candidate in early-stage trials for solid tumors. Investors track the company for its novel approach to delivering radiation directly to tumor cells while sparing healthy tissue.
52W Range: $14.72-$34.19
Congressional Interest in Aktis Oncology, Inc. (AKTS)
No congressional trades have been disclosed for Aktis Oncology, Inc. (AKTS) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading AKTS?
No congressional trades found for this stock.